Member Info for Shukan

Not for shareholders

Dr Vlad in London today -

Latest “Is it possible to stop cancer by pushing malignant cells into senescence?!?” https://en.wikipedia.org/wiki/Cellular_senescence

Indeed- I refer you to my previous tweet, now for those that can bothered to research the latest tweet from Dr Sandler is hugely significant, I’ll give you a clue this time last year what was tweeted out of Hemogenyx,s Lab ?

I had a long face to face chat with Dr Robin Campbell, last year in this very subject CAR-T, hence my comment below ,
I will go with the qualified good doctors conversation rather than the unqualified commentary on here thank you.
Hemogenyx are on a different path.

CAR-T therapy nothing whatsoever to do with what Hemogenyx is developing

Agreed the SP at all time lows and an £80K bonus - there is a phrase for this.

came to market at 3.5p

Market waking up

https://www.orgenesis.com/news-media/press-releases/detail/106/orgenesis-subsidiary-masthercell-global-expands-production

https://www.orgenesis.com/news-media/press-releases/detail/102/orgenesis-announces-collaboration-with-hemogenyx-to-develop

Follow Masthercell - an off shoot of Orgenesis , and very important to Hemogenyx- anyone selling this down here should not be in stocks , or just can’t understand what’s going on either way last lot I loaded up at 2.25p something to thank sellers for

What I have found ‪@MaSTherCell ‬- now go and do the research - hope you lot have been loading up down here

Positive RNS this morning- a long read for the long road ahead

October 2019 warrants runout - Only £38K down , Merry Christmas see u in the NYear

Look beyond that

https://www.youtube.com/watch?v=QIuZmWT3MvE

And look what we have here👇👇👇 GERMANTOWN, Md., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a developer, service provider and manufacturer of advanced cell therapies, today announced that it has entered into a collaboration agreement with the New York Blood Center (NYBC), one of the largest independent, community-based blood centers in the world. Under the agreement, NYBC will be responsible for establishing the infrastructure to collect, process, test, cryopreserve and biobank sampling materials, including liver biopsies. The samples are intended for use as source of autologous insulin producing (AIP) cells for patients that may be eligible for future clinical trials.

I have a really big chunk else where - taken some out here to take advantage of the drop over there - since I bought them below .3- it’s not blah blah it called been upfront - I have quite a chunk left here - anyway stop crying relax and enjoy the ride

yeah I've pulled quite few out now was expecting the update last week- other opportunities around